Phase I/II study of TLR7 agonist imiquimod and radiotherapy in Breast Cancer Patients with Chest Wall Recurrence or Skin Metastases

The cell killing and immunostimulatory properties of two local treatment modalities, radiotherapy (RT) and Imiquimod (IMQ), may generate an effective immune response and lead to systemic control of breast cancer after local treatment of the cancer on the skin spread from the breast (skin metastases). This study is to find an optimal dose of IMQ in the first part and test the effectiveness of the combination treatment of RT and IMQ in patients with skin metastases from breast cancer in the second part

Learn more about this clinical trial at cancer.gov.

Contact

Sylvia Adams, MD
212-263-4432
sylvia.adams@nyumc.org

Maria Fenton-Kerimian, APN-bc, OCN
212-731-5035
maria.fenton-kerimian@nyumc.org